• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Prescription Drugs-List Price, Net Price, and the Rebate Caught in the Middle.

作者信息

Dusetzina Stacie B, Bach Peter B

机构信息

Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee.

Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.

出版信息

JAMA. 2019 Apr 23;321(16):1563-1564. doi: 10.1001/jama.2019.2445.

DOI:10.1001/jama.2019.2445
PMID:30840047
Abstract
摘要

相似文献

1
Prescription Drugs-List Price, Net Price, and the Rebate Caught in the Middle.处方药——标价、净价与处于中间环节的回扣
JAMA. 2019 Apr 23;321(16):1563-1564. doi: 10.1001/jama.2019.2445.
2
Specialty Drug Pricing and Out-of-Pocket Spending on Orally Administered Anticancer Drugs in Medicare Part D, 2010 to 2019.2010 年至 2019 年医疗保险部分 D 中口服抗癌药物的特殊药物定价和自付支出。
JAMA. 2019 May 28;321(20):2025-2027. doi: 10.1001/jama.2019.4492.
3
Reimbursement to Pharmacies for Generic Drugs by Medicare Part D Sponsors.医疗保险D部分赞助商对药店通用药物的报销。
JAMA. 2023 Dec 26;330(24):2390-2392. doi: 10.1001/jama.2023.21481.
4
Role of Specialty Drugs in Rising Drug Prices for Medicare Part D.特殊药物在医疗保险处方药部分药物价格上涨中的作用。
JAMA Health Forum. 2024 May 3;5(5):e241188. doi: 10.1001/jamahealthforum.2024.1188.
5
Rebates-The Little-Known Factor Behind Increasing Drug List Prices.回扣——药品目录价格上涨背后鲜为人知的因素。
JAMA. 2020 Mar 3;323(9):812-813. doi: 10.1001/jama.2020.1208.
6
A New Safe Harbor - Turning Drug Rebates into Discounts in Medicare Part D.一个新的安全港——将药品回扣转化为医疗保险D部分的折扣
N Engl J Med. 2019 May 2;380(18):1688-1690. doi: 10.1056/NEJMp1902692. Epub 2019 Apr 3.
7
Impacts of generic competition and benefit management practices on spending for prescription drugs: evidence from Medicare's Part D benefit.仿制药竞争和效益管理措施对处方药支出的影响：来自医疗保险D部分福利的证据。
Medicare Medicaid Res Rev. 2014 Jan 2;4(1). doi: 10.5600/mmrr.004.01.a01. eCollection 2014.
8
Pharmaceuticals and medical devices: Medicare Part D. Issue brief.药品和医疗器械：医疗保险D部分。问题简报。
Issue Brief Health Policy Track Serv. 2012 Dec 31:1-32.
9
Estimated Changes in Manufacturer and Health Care Organization Revenue Following List Price Reductions for Hepatitis C Treatments.预计降低丙型肝炎治疗药物的建议零售价后，制造商和医疗机构收入的变化。
JAMA Netw Open. 2019 Jul 3;2(7):e196541. doi: 10.1001/jamanetworkopen.2019.6541.
10
Recommendations for Lowering Prescription Drug Spending in Public Programs.降低公共项目中处方药支出的建议。
Ann Intern Med. 2019 Dec 3;171(11):855-856. doi: 10.7326/M19-2895. Epub 2019 Nov 12.

引用本文的文献

1
Use and Cost of First-Line Biologic Medications to Treat Plaque Psoriasis in the US.美国一线生物药物治疗斑块状银屑病的使用情况及成本
JAMA Dermatol. 2025 Apr 16. doi: 10.1001/jamadermatol.2025.0669.
2
Association of Direct-to-Consumer Advertising of Prescription Drugs With Consumer Health-Related Intentions and Beliefs Among Individuals at Risk of Cardiovascular Disease.直接面向消费者的处方药广告与心血管疾病风险人群的消费者健康相关意图和信念的关联。
JAMA Health Forum. 2022 Aug 5;3(8):e222570. doi: 10.1001/jamahealthforum.2022.2570.
3
Association of Branded Prescription Drug Rebate Size and Patient Out-of-Pocket Costs in a Nationally Representative Sample, 2007-2018.
2007-2018 年，全国代表性样本中品牌处方药回扣规模与患者自付费用的关联。
JAMA Netw Open. 2021 Jun 1;4(6):e2113393. doi: 10.1001/jamanetworkopen.2021.13393.
4
Association of Drug Rebates and Competition With Out-of-Pocket Coinsurance in Medicare Part D, 2014 to 2018.2014 年至 2018 年期间，医疗保险处方药部分的药品回扣和竞争与自付共付额的关系。
JAMA Netw Open. 2021 May 3;4(5):e219030. doi: 10.1001/jamanetworkopen.2021.9030.
5
Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs.品牌药价格变化与患者自付费用的相关性。
JAMA Netw Open. 2021 May 3;4(5):e218816. doi: 10.1001/jamanetworkopen.2021.8816.
6
Budget Impact of Adaptive Abiraterone Therapy for Castration-Resistant Prostate Cancer.阿比特龙适应性疗法用于去势抵抗性前列腺癌的预算影响
Am Health Drug Benefits. 2021 Mar;14(1):15-20.
7
Pharmacologic, Dietary, and Psychological Treatments for Irritable Bowel Syndrome With Constipation: Cost Utility Analysis.便秘型肠易激综合征的药物、饮食及心理治疗：成本效用分析
MDM Policy Pract. 2021 Jan 18;6(1):2381468320978417. doi: 10.1177/2381468320978417. eCollection 2021 Jan-Jun.
8
Payment incentives and the use of higher-cost drugs: a retrospective cohort analysis of intravenous iron in the Medicare population.支付激励与高成本药物的使用：医疗保险人群中静脉铁剂的回顾性队列分析。
Am J Manag Care. 2020 Dec;26(12):516-522. doi: 10.37765/ajmc.2020.88539.
9
Changes in Drug List Prices and Amounts Paid by Patients and Insurers.药品目录价格和患者及保险公司支付金额的变化。
JAMA Netw Open. 2020 Dec 1;3(12):e2028510. doi: 10.1001/jamanetworkopen.2020.28510.
10
Variation in generic dispensing rates in Medicare Part D.医疗保险处方药中仿制药配给率的差异。
Am J Manag Care. 2020 Nov 1;26(11):e355-e361. doi: 10.37765/ajmc.2020.88530.